Integrated pharmaceutical company, Nectar Lifesciences is awaiting the United States Food and Drug Administration (USFDA) inspection for it's active pharmaceutical ingredient (API) bulk pharma plant.
In an interview with CNBC-TV18, Dinesh Dua, CEO of Nectar Lifesciences said, "ItDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!